Rho kinase activation and gene expression related to vascular remodeling in normotensive rats with high angiotensin I-converting enzyme levels

Hypertension

Volumn 50, Issue 4, 2007, Pages 792-798

  Rivera, Paulina ^a   Ocaranza, María Paz ^a   Lavandero, Sergio ^b   Jalil, Jorge E ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Angiotensin; Angiotensin converting enzyme; Fasudil; Hypertension; NADPH; Remodeling; Rho kinase

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; FASUDIL; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; OXYGEN; PLASMINOGEN ACTIVATOR INHIBITOR; RHO KINASE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; AORTA WALL; BLOOD PRESSURE; BLOOD VESSEL WALL; BROWN NORWAY RAT; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HYPERTENSION; LEWIS RAT; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANGIOTENSIN II; ANIMALS; AORTA; BLOOD PRESSURE; CHEMOKINE CCL2; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; OXIDATIVE STRESS; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, INBRED BN; RATS, INBRED LEW; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR REMODELING;

EID: 34548853983     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.095117     Document Type: Conference Paper

References (53)

1. Jacobs M, Hayakawa K, Swenson L, Bellon S, Fleming M, Taslimi P, Doran J. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J Biol Chem. 2006;281:260-260.
2. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005;25:1767-1775.
3. Jalil JE, Lavandero S, Chiong M, Ocaranza MP. Rho/Rho kinase signal transduction pathway in cardiovascular disease and cardiovascular remodeling. Rev Esp Cardiol. 2005;58:951-961.
4. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 2001;15:1062-1064.
5. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci. 2001;22:32-39.
6. Hall A. Rho GTPase and the actin cytoskeleton. Science. 1998;279:509-514.
7. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science. 1997;275:1308-1311.
8. van Nieuw Amerongen GP, van Hinsbergh VWM. Cytoskeletal effects of Rho-like small guanine nucleotide-binding proteins in the vascular system. Arterioscler Thromb Vasc Biol. 2001;21:300-311.
9. Horwitz AR, Parsons JT. Cell migration: movin' on. Science. 1999;286:1102-1103.
10. Narumiya S. The small GTPase Rho: cellular functions and signal transduction. J Biochem (Tokyo). 1996;120:215-228.
11. Seko T, Ito M, Kureishi Y, Okamoto R, Moriki N, Onishi K, Isaka N, Hartshorne DJ, Nakano T. Activation of Rho A and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res. 2003;92:411-418.
12. Jin L, Ying Z, Webb RC. Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am J Physiol Heart Circ Physiol. 2004;287:1495-1500.
13. Lee DL, Clinton Webb R, Jin L. Hypertension and RhoA/Rho kinase signaling in the vasculature. Hypertension. 2004;44:796-799.
14. Feng J, Ito M, Ichikawa K, Isaka N, Nishikawa M, Hartshorne DJ, Nakano T. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem. 1999;274:37385-37390.
15. Radeff JM, Nagy Z, Stern PH. Rho and Rho kinase are involved in parathyroid hormone-stimulated protein kinase C alpha translocation and IL-6 promotor activity in osteoblast cells. J Bone Mineral Res. 2004;19:1882-1891.
16. Funakoshi Y, Ichiki T, Shimokawa H, Egashira K, Kaibuchi K, Takeya M, Yoshimura T, Takeshita A. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension. 2001;38:100-104.
17. Beswick R, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticiod hypertensive rat. Hypertension. 2001;38:1107-1115.
18. Fortuño A, Olivan S, Beloqui O, San Jose G, Moreno MU, Diez J, Zalba G. Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens. 2004;22:2169-2175.
19. Takeda K, Ichiki T, Tokunou T, Iino N, Fujii S, Kitabatake A, Shimokawa H, Takeshita A. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor-1 gene expression. Arterioscler Thromb Vasc Biol. 2001;21:868-873.
20. Matsumoto Y, Uwatoku T, Abe K, Oi K, Hattori T, Morishige K, Eto Y, Fukumoto Y, Nakamura K, Shibata Y, Matsuda T, Takeshita A, Shimokawa H. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries. Involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol. 2004;24:181-186.
21. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Kaibuchi K, Takeshita A. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res. 2004;94:46-52.
22. Taniyama Y, Griendling K. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42:1075-1081.
23. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002;106:57-62.
24. Zhou Y, Chen Y, Dirksen WP, Morris M, Periasamy M. AT1b receptor predominantly mediates contractions in major mouse blood vessels. Circ Res. 2003;93:1089-1094.
25. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Effects on endothelial NAD(P)H oxidase system. Circ Res. 2003;93:767-775.
26. Yamakawa T, Tanaka S, Numaguchi K, Yamakawa Y, Motley ED, Ichihara S, Inagami T. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension. 2000;35:313-318.
27. Jalil JE, Ocaranza MP. Genotypes of the renin-angiotensin-aldosterone system: on the search of cardiovascular diseases. Rev Esp Cardiol. 2002;55:89-91.
28. Jalil JE, Palomera C, Ocaranza MP, Godoy I, Roman M, Chiong M, Lavandero S. Levels of plasma angiotensin-(1-7) in patients with hypertension who have the angiotensin-I-converting enzyme deletion/deletion genotype. Am J Cardiol. 2003;92:749-751.
29. Jalil JE, Cordova S, Ocaranza M, Schumacher E, Braun S, Chamorro G, Fardella C, Lavandero S. Angiotensin I-converting enzyme insertion/ deletion polymorphism and adrenergic response to exercise in hypertensive patients. Med Sci Monit. 2002;8:CR566-CR571.
30. Pueyo ME, Challah M, Gauguier D, Louedec L, Philippe M, Gaertner R, Marre M, Michel JB, Jacob MP. Transforming growth factor-beta 1 production is correlated with genetically determined ACE expression in congenic rats: a possible link between ACE genotype and diabetic nephropathy. Diabetes. 2004;53:1111-1118.
31. Jalil JE, Perez A, Ocaranza MP, Bargetto J, Galaz A, Lavandero S. Increased aortic NADPH oxidase activity in rats with genetically high angiotensin-converting enzyme levels. Hypertension. 2005;46:1362-1367.
32. Ocaranza MP, Piddo AM, Faundez P, Lavandero S, Jalil JE. Angiotensin I-converting enzyme gene polymorphism influences chronic hypertensive response in the rat Goldblatt model. J Hypertens. 2002;20:413-420.
33. Ocaranza MP, Palomera C, Roman M, Bargetto J, Lavandero S, Jalil JE. Effect of hypertension on angiotensin-(1-7) levels in rats with different angiotensin-I converting enzyme polymorphism. Life Sci. 2006;78:1535-1542.
34. Oliveri C, Ocaranza MP, Campos X, Lavandero S, Jalil J. Angiotensin I-converting enzyme modulates neutral endopeptidase activity in the rat. Hypertension. 2001;38:650-654.
35. Ocaranza MP, Diaz-Araya G, Carreno JE, Munoz D, Riveros JP, Jalil JE, Lavandero S. Polymorphism in gene coding for ACE determines different development of myocardial fibrosis in rats. Am J Physiol. 2004;H286:498-506.
36. Challah M, Villard E, Philippe M, Ribadeau-Dumas A, Giraudeau B, Janiak P, Vilaine JP, Soubrier F, Michel JB. Angiotensin I-converting enzyme genotype influences arterial response to injury in normotensive rats. Arterioscler Thromb Vasc Biol. 1998;18:235-243.
37. Bradford MM. A rapid and sensitive method for the quantitation of microgram cuantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
38. Song J, Kost CK Jr, Martin DS. Androgens potentiate renal vascular responses to angiotensin II via amplification of the Rho kinase signaling pathway. Cardiovasc Res. 2006;72:456-463.
39. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, Kimura S, Kiyomoto H, Ohmori K, Li DT, Abe Y, Nishiyama A. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol. 2006;17:2193-2201.
40. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res. 2007;100:923-929.
41. Ammarguellat F, Larouche I, Schiffrin EL. Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Circulation. 2001;103:319-324.
42. Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci. 2007;28:296-302.
43. Kobayashi N, Nakano S, Mita SI, Kobayashi T, Honda T, Tsubokou Y, Matsuoka H. Involvement of Rho-kinase phathway for angiotensin II induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats. J Pharmacol Exp Therap. 2002;301:459-466.
44. Kataoka C, Egashira K, Inoue S, Takemoto M, Ni W, Koyanagi M, Kitamoto S, Usui. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 2002;39:245-250.
45. Kanda T, Hayashi K, Wakino S, Homma K, Yoshioka K, Hasegawa K, Sugano N, Tatematsu S, Takamatsu I, Mitsuhashi T, Saruta T. Role of Rho-kinase and p27 in angiotensin II-induced vascular injury. Hypertension. 2005;45:724-729.
46. Wang Y, Martin-McNulty B, da Cunha V, Vincelette J, Lu X, Feng Q, Halks-Miller M, Mahmoudi M, Schroeder M, Subramanyam B, Tseng J, Deng G, Schirm S, Johns A, Kauser K, Dole WP, Light DR. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin I-induced abdominal aortic aneurysm in apolipoprotein E-Deficient mice by inhibiting apoptosis and proteolysis. Circulation. 2005;111:2219-2226.
47. Nohria A, Grunert ME, Rikitake Y, Noma K, Prsic A, Ganz P, Liao JK, Creager MA. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res. 2006;99:1426-1432.
48. Otsuka T, Ibuki C, Suzuki T, Ishii K, Kodani E. Atarashi H, Kishida H, Takano T. Vasodilatory effect of subsequent administration of fasudil, a Rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris. Circ J. 2006;70:402-408.
49. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98:322-334.
50. O'Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ, Myers RH, Levy D. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation. 1998;97:1766-1772.
51. Higaki J, Baba S, Katsuya T, Sato N, Ishikawa K, Mannami T, Ogata J, Ogihara T. Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in japanese men. The Suita Study. Circulation. 2000;101:2060-2065.
52. Amant C, Bauters C, Bodart JC, Lablanche JM, Grollier G, Danchin N, Hamon M, Richard F, Helbecque N, McFadden EP, Amouyel P, Bertrand ME. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation. 1997;96:56-60.
53. Guarda E, Fajuri A, Marchant E, Martinez A, Jalil J, Illanes G, Vecchiola A, Lazen R, Flores A, Barra V, Irarrazabal S, Ilabaca F. D/D genotype of the gene for angiotensin converting enzyme as a risk factor for post-stent coronary restenosis. Rev Esp Cardiol. 1999;52:475-480.